Literature DB >> 30833828

The case for radiotherapy in a Value based environment.

Peter A S Johnstone1,2, Susan Peneguy1, Timothy N Showalter3, James B Yu4.   

Abstract

AIM: Describe the Value proposition for radiotherapy (RT) in the United States.
BACKGROUND: In the United States since 2005, two forces have worked to decrease RT cost per patient: Federal changes in reimbursement and hypofractionation of treatment courses. We theorize that these have driven stable reimbursement in the context of increasing technology of intensity modulation (IMRT) and image guidance (IGRT). This phenomenon provides increasing Value of the discipline to patients and systems.
MATERIALS AND METHODS: We searched the Medicare Physician/Supplier data for Program Payments per Person with Utilization for 2000 through 2016. This involves two databases: Enrollment Database (EDB) for 2000-2012 and Common Medicare Enrollment (CME) since 2013. RT payments to individual patients accessing services were retrieved.
RESULTS: Taking into account the change of calculation algorithm used by CMS in 2013, costs per patient were similar in 2012 and 2003, and 2016 and 2013.
CONCLUSIONS: In the United States, stabilizing costs in the face of increasing work, better outcomes, and decreased toxicity contributes to increasing RT value over the past 10 years.

Entities:  

Keywords:  Health services research; Radiation oncology; Value

Year:  2019        PMID: 30833828      PMCID: PMC6384322          DOI: 10.1016/j.rpor.2019.01.006

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  23 in total

1.  Patient preferences and physician practice patterns regarding breast radiotherapy.

Authors:  David J Hoopes; David Kaziska; Patrick Chapin; Daniel Weed; Benjamin D Smith; E Ronald Hale; Peter A Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

Review 2.  Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline.

Authors:  Stephen Lutz; Lawrence Berk; Eric Chang; Edward Chow; Carol Hahn; Peter Hoskin; David Howell; Andre Konski; Lisa Kachnic; Simon Lo; Arjun Sahgal; Larry Silverman; Charles von Gunten; Ehud Mendel; Andrew Vassil; Deborah Watkins Bruner; William Hartsell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

3.  Global reluctance to practice evidence-based medicine continues in the treatment of uncomplicated painful bone metastases despite level 1 evidence and practice guidelines.

Authors:  Edward Chow; Carol A Hahn; Stephen T Lutz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-01       Impact factor: 7.038

4.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

5.  Radiation oncology services in the modern era: evolving patterns of usage and payments in the office setting for medicare patients from 2000 to 2010.

Authors:  Xinglei Shen; Timothy N Showalter; Mark V Mishra; Sanford Barth; Vijay Rao; David Levin; Laurence Parker
Journal:  J Oncol Pract       Date:  2014-04-22       Impact factor: 3.840

6.  Adoption of hypofractionated whole-breast irradiation for early-stage breast cancer: a National Cancer Data Base analysis.

Authors:  Elyn H Wang; Sarah S Mougalian; Pamela R Soulos; Charles E Rutter; Suzanne B Evans; Bruce G Haffty; Cary P Gross; James B Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-08-19       Impact factor: 7.038

7.  How effective are clinical pathways with and without online peer-review? An analysis of bone metastases pathway in a large, integrated National Cancer Institute-Designated Comprehensive Cancer Center Network.

Authors:  Sushil Beriwal; Malolan S Rajagopalan; John C Flickinger; Susan M Rakfal; Edwin Rodgers; Dwight E Heron
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-13       Impact factor: 7.038

Review 8.  Surgical and ablative therapies for the management of adrenal 'oligometastases' - A systematic review.

Authors:  Ashray Gunjur; Cuong Duong; David Ball; Shankar Siva
Journal:  Cancer Treat Rev       Date:  2014-04-16       Impact factor: 12.111

9.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.

Authors:  Kyle E Rusthoven; Brian D Kavanagh; Stuart H Burri; Changhu Chen; Higinia Cardenes; Mark A Chidel; Thomas J Pugh; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.

Authors:  Kyle E Rusthoven; Brian D Kavanagh; Higinia Cardenes; Volker W Stieber; Stuart H Burri; Steven J Feigenberg; Mark A Chidel; Thomas J Pugh; Wilbur Franklin; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

View more
  1 in total

1.  Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.

Authors:  Ya-Chen Tina Shih; Ying Xu; Cathy Bradley; Sharon H Giordano; James Yao; K Robin Yabroff
Journal:  J Natl Cancer Inst       Date:  2022-10-06       Impact factor: 11.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.